CN109504024B - SEBS (styrene-ethylene-butylene-styrene) based granules, preparation method thereof, extrusion film for infusion apparatus and infusion apparatus - Google Patents
SEBS (styrene-ethylene-butylene-styrene) based granules, preparation method thereof, extrusion film for infusion apparatus and infusion apparatus Download PDFInfo
- Publication number
- CN109504024B CN109504024B CN201811488901.4A CN201811488901A CN109504024B CN 109504024 B CN109504024 B CN 109504024B CN 201811488901 A CN201811488901 A CN 201811488901A CN 109504024 B CN109504024 B CN 109504024B
- Authority
- CN
- China
- Prior art keywords
- sebs
- vitamin
- infusion
- preparation
- adsorption
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L53/00—Compositions of block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers
- C08L53/02—Compositions of block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers of vinyl-aromatic monomers and conjugated dienes
- C08L53/025—Compositions of block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers of vinyl-aromatic monomers and conjugated dienes modified
Abstract
The invention provides SEBS (styrene-ethylene-butylene-styrene) based granules, a preparation method thereof, an extrusion film for an infusion apparatus and an infusion apparatus. The SEBS-based granules provided by the invention are prepared by blending and granulating the following raw materials in parts by weight: 50-100 parts of SEBS; 0-40 parts of dopamine; 0-40 parts of SEBS-g-Ma; 2-30 parts of a vitamin E-based compound; the vitamin E-based compound is selected from one or more of vitamin E and vitamin E derivatives; the content of the dopamine and the SEBS-g-Ma is not 0 at the same time. According to the invention, SEBS is used as a base material, and is matched with dopamine, SEBS-g-Ma and a vitamin E-based compound in a certain proportion to prepare granules, and the obtained material can effectively inhibit the adsorption of butylphthalide and improve the adsorption phenomenon of a SEBS infusion apparatus on the butylphthalide; in addition, the granular material has simple components, does not need various complex auxiliary agents, has low cost and avoids the risk of side reaction with the medicine.
Description
Technical Field
The invention relates to the technical field of medical materials, and particularly relates to SEBS (styrene-ethylene-butadiene-styrene) based granules, a preparation method thereof, an extrusion film for an infusion apparatus and an infusion apparatus.
Background
According to statistics, the number of death people due to acute cerebral arterial thrombosis reaches 150 million in China every year, and the death people rise year by year, and intravenous injection of butylphthalide sodium chloride injection is a common solution at present. The infusion apparatus is a basic tool for implementing intravenous injection, and common infusion apparatuses in the market comprise polyethylene infusion apparatuses, polyvinyl chloride infusion apparatuses, polypropylene infusion apparatuses and the like, but the p-butylphthalide has adsorption at different degrees, and the stability of the materials is low.
In recent years, the styrene thermoplastic elastomer (TPE) attracts the attention of many researchers due to the advantages of good aging resistance, thermal stability, high transparency and the like, and in practical application, a TPE infusion set has replaced a polyvinyl chloride infusion set and is used for intravenous injection of a butylphthalide sodium chloride injection, so that the preparation of a TPE infusion set with high-efficiency butylphthalide adsorption inhibition is imperative.
Along with the improvement of attention of people to the wall hanging phenomenon of the infusion apparatus, the research and development of the infusion apparatus with certain medicine adsorption inhibiting capacity are also advanced to a certain extent. For example, in patent CN101798433A, SEBS, PP, filling oil, antioxidant, etc. are melt blended by means of blending to prepare a medical infusion product with few surface precipitates, low drug adsorption, light weight, and convenient use, and it is worth mentioning that the infusion set of the present invention does not react with anticancer drugs such as paclitaxel, and is mainly used for the delivery of anticancer drugs. The patent CN 101537216 adopts a co-extrusion blow molding method to prepare a polyurethane/polyvinyl chloride double-layer infusion set, and compared with a single polyvinyl chloride infusion set, the composite infusion set material has low drug adsorption amount and no harmful components such as additives.
However, the above solutions all have certain disadvantages, and the method for preparing the infusion set is blending modification, and needs to add a series of auxiliary agents to achieve the effect of inhibiting drug adsorption, and the method has high cost and complex operation, and the addition of a series of auxiliary agents may react with the drug, so that the effect of inhibiting adsorption is not good enough, and the method does not meet the requirement of environmental protection.
Disclosure of Invention
In view of the above, the present invention aims to provide SEBS-based pellets, a preparation method thereof, an extrusion film for infusion devices, and an infusion device. The SEBS-based granular material provided by the invention has the advantages of simple components, low cost, simple preparation and excellent drug adsorption inhibition effect.
The invention provides SEBS-based granules which are prepared by blending and granulating the following raw materials in parts by weight:
the vitamin E-based compound is selected from one or more of vitamin E and vitamin E derivatives;
the content of the dopamine and the SEBS-g-Ma is not 0 at the same time.
Preferably, the number average molecular weight Mn of the SEBS is 70000-120000;
the grafting rate of Ma in the SEBS-g-Ma is 0.2-4%.
Preferably, the SEBS brand comprises YH506,
G1652 and
7311F;
the designation of SEBS-g-Ma includes FG 1901.
Preferably, the vitamin E derivative is vitamin E polyethylene glycol succinate and/or polyethoxy vitamin E.
Preferably, the raw material further comprises polypropylene; the mass ratio of the SEBS to the polypropylene is 70: 10-50.
The invention also provides a preparation method of the SEBS-based granules in the technical scheme, which is characterized by comprising the following steps:
a) melting and blending the raw materials to obtain a blend;
b) and extruding and granulating the blend to obtain SEBS-based granules.
Preferably, the temperature of the melt blending is 160-180 ℃, and the time is 5-10 min.
Preferably, before the melt blending, drying the raw materials;
the drying temperature of the raw materials is 40-120 ℃, and the drying time is 2-12 hours;
after the melt blending, further comprising drying the blend; the drying temperature of the blend is 40-80 ℃, and the drying time is 2-12 h.
The invention also provides an extrusion film for the infusion apparatus, which is prepared from the SEBS-based granules in the technical scheme or the SEBS-based granules prepared by the preparation method in the technical scheme through extrusion blow molding.
The invention also provides an infusion apparatus, which comprises a dropping funnel and an infusion tube, wherein the dropping funnel and/or the infusion tube are/is prepared by extrusion blow molding of SEBS-based granules;
the SEBS-based granules are the SEBS-based granules in the technical scheme or the SEBS-based granules prepared by the preparation method in the technical scheme.
The invention provides SEBS-based granules which are prepared by blending and granulating the following raw materials in parts by weight: 50-100 parts of SEBS; 0-40 parts of dopamine; 0-40 parts of SEBS-g-Ma; 2-30 parts of a vitamin E-based compound; the vitamin E-based compound is selected from one or more of vitamin E and vitamin E derivatives; the content of the dopamine and the SEBS-g-Ma is not 0 at the same time. According to the invention, SEBS is used as a base material, and is matched with dopamine, SEBS-g-Ma and a vitamin E-based compound in a certain proportion to prepare granules, the obtained material can effectively inhibit adsorption of butylphthalide, the phenomenon of wall-hanging adsorption of the SEBS infusion apparatus on the butylphthalide is greatly improved, the utilization rate of the medicine can be improved, and the economic burden of a patient can be reduced; in addition, the granular material has simple components, does not need various complex auxiliary agents, has low cost and avoids the risk of side reaction with the medicine.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to the provided drawings without creative efforts.
FIG. 1 is a flow chart of the preparation of example 1;
FIG. 2 is a standard curve of butylphthalide in example 5;
FIG. 3 is a comparative chart of adsorptivity of example 5.
Detailed Description
The invention provides SEBS-based granules which are prepared by blending and granulating the following raw materials in parts by weight:
the vitamin E-based compound is selected from one or more of vitamin E and vitamin E derivatives;
the content of the dopamine and the SEBS-g-Ma is not 0 at the same time.
According to the invention, the SEBS is used as a base material, and is matched with dopamine, SEBS-g-Ma and a vitamin E-based compound in a certain proportion to prepare granules, the obtained material can reduce or even inhibit adsorption of butylphthalide in the injection on the surface of a transfusion membrane, so that the drug effect loss is reduced on the basis of not influencing the drug quality, the drug utilization rate is improved, and the economic burden of a patient is relieved; in addition, the granular material has simple components, does not need various complex auxiliary agents, has low cost and avoids the risk of side reaction with the medicine.
In the present invention, the raw material of the SEBS-based pellet includes SEBS. The SEBS is a linear triblock copolymer which takes polystyrene as a tail end and takes an ethylene-butylene copolymer obtained by hydrogenation of polybutadiene as a middle elastic block, is a thermoplastic elastomer, has good transparency, thermoplasticity and aging resistance, has simple production process and low cost, and is suitable for preparing infusion set materials. In the invention, the source of the SEBS is not particularly limited, and the SEBS can be a general commercial product.
Preferably, the number average molecular weight Mn of the SEBS is 70000-120000. More preferably, the SEBS brand comprises YH506,
G1652 and
7311F.
The content of the SEBS is 50-100 parts by weight, and more preferably 60-100 parts by weight.
In the present invention, the raw material of the SEBS-based pellet includes dopamine. The source of the dopamine is not particularly limited, and the dopamine is available on the market. In the invention, the content of the dopamine is 0-40 parts by weight.
In the present invention, the raw material of the SEBS-based pellet includes SEBS-g-Ma. The SEBS-g-Ma is SEBS grafted by maleic anhydride. In the present invention, the graft ratio of Ma (i.e., the graft ratio of maleic anhydride) in the SEBS-g-Ma is preferably 0.2% to 4%, more preferably 1% to 3%. In some embodiments of the invention, the SEBS-g-Ma is named Keteng FG 1901. In the invention, the content of the SEBS-g-Ma is 0-40 parts by weight.
In the invention, the content of the dopamine and the SEBS-g-Ma is not 0 at the same time. In some embodiments of the invention, the dopamine content is 2-40 parts by weight, and the SEBS-g-Ma content is 0; in a preferred embodiment, the dopamine content is 5-10 parts by weight, and the SEBS-g-Ma content is 0. In other embodiments of the invention, the SEBS-g-Ma content is 2-40 parts by weight, and the dopamine content is 0; in a preferred embodiment, the SEBS-g-Ma content is 5-20 parts by weight, and the dopamine content is 0.
In the present invention, the raw material of the SEBS-based pellet includes a vitamin E-based compound. The vitamin E-based compound is selected from one or more of vitamin E and vitamin E derivatives; more preferably a vitamin E derivative. The vitamin E-based compound is introduced into the SEBS-based system, and can inhibit the adsorption of the material on butylphthalide under the synergistic effect with dopamine or SEBS-g-Ma; wherein, the vitamin E-based compound has obvious absorption inhibiting effect when being a vitamin E derivative.
In the present invention, the vitamin E derivative is preferably vitamin E polyethylene glycol succinate and/or polyethoxy vitamin E. The structure of the vitamin E polyethylene glycol succinate is shown as a formula (1), and the structure of the polyethoxy vitamin E is shown as a formula (2):
the amphiphilic vitamin E derivative obtained by combining polyethylene glycol and vitamin E can effectively inhibit the adsorption of butylphthalide. The source of the vitamin E derivative is not particularly limited in the invention, and the vitamin E derivative can be general commercial products or prepared according to preparation methods well known to those skilled in the art, such as vitamin E polyethylene glycol succinate, and can be prepared by esterification reaction of vitamin E succinic acid and PEG (namely polyethylene glycol); the polyethoxy vitamin E can be prepared by ring-opening reaction of ethylene oxide and vitamin E.
In the present invention, the content of the vitamin E-based compound is 2 to 30 parts by weight, preferably 5 to 10 parts by weight.
In the invention, the raw material of the SEBS-based granules also comprises polypropylene (namely PP), and the polypropylene can be added to co-extrude the infusion tube with the SEBS base material, so that the basic performance of the infusion tube is improved. In the invention, the mass ratio of the SEBS to the polypropylene is preferably 70: 10-50, more preferably 70: 20-40, and most preferably 70: 30.
According to the invention, SEBS is used as a base material, and is matched with dopamine, SEBS-g-Ma and a vitamin E-based compound in a certain proportion to prepare granules, and the vitamin E-based compound and the dopamine or SEBS-g-Ma have a synergistic effect, so that the SEBS base material can effectively inhibit the adsorption of butylphthalide, the phenomenon of the adsorption of the butylphthalide by an SEBS infusion apparatus is greatly improved, the utilization rate of medicines is improved, and the economic burden of a patient is relieved; in addition, the granular material has simple components, does not need various complex auxiliary agents, has low cost and avoids the risk of side reaction with the medicine.
The invention also provides a preparation method of the SEBS-based granules, which comprises the following steps:
a) melting and blending the raw materials to obtain a blend;
b) and extruding and granulating the blend to obtain SEBS-based granules.
The component types, proportions and the like of the raw materials are consistent with those in the technical scheme, and are not repeated herein.
In the present invention, it is preferable to dry the raw materials before melt blending. The drying temperature of the raw materials is preferably 40-120 ℃, and more preferably 50-80 ℃; the drying time is preferably 2-12 h, and more preferably 4-8 h. Drying the raw materials, preferably mixing, and uniformly mixing to obtain a mixture.
And after obtaining the mixture, melting and blending the mixture to obtain a blend. The temperature of the melt blending is preferably 160-180 ℃; the time for melt blending is preferably 5-10 min.
After the blend is obtained, it is preferably also dried. The drying temperature of the blend is preferably 40-80 ℃, more preferably 40-60 ℃, and the time is preferably 2-12 hours, more preferably 2-4 hours.
After the drying, the blend was extruded to pelletize to obtain SEBS-based pellets. The extrusion granulation method is not particularly limited, and may be performed according to a conventional extrusion granulation method well known to those skilled in the art. After the extrusion granulation, SEBS-based granules are obtained and can be used for molding other various materials. In the invention, the particle size of the SEBS-based granules is not particularly limited, and in the embodiment of the invention, the SEBS-based granules are cylindrical granules with the length of 3-4 mm and the diameter of 2-3 mm.
The invention also provides an extrusion film for the infusion apparatus, which is prepared from the SEBS-based granules in the technical scheme or the SEBS-based granules prepared by the preparation method in the technical scheme through extrusion blow molding. The obtained extruded film can effectively inhibit the adsorption of butylphthalide, greatly improve the adsorption phenomenon of the SEBS infusion apparatus to the butylphthalide, improve the utilization rate of medicaments and reduce the economic burden of patients. The manner of the extrusion blow molding is not particularly limited in the present invention, and may be performed in an extrusion blow molding manner well known to those skilled in the art. Such as by means of conventional extrusion equipment, in particular a single-screw extruder. In some embodiments of the present invention, the extrusion blow molding is performed by using a single screw extruder, wherein the head temperature is 160-200 ℃, the barrel temperature is 180-190 ℃, and the residence time is 10 minutes.
The invention also provides an infusion apparatus, which comprises a dropping funnel and an infusion tube, wherein the dropping funnel and/or the infusion tube are/is prepared by extrusion blow molding of SEBS-based granules; the SEBS-based granules are the SEBS-based granules in the technical scheme or the SEBS-based granules prepared by the preparation method in the technical scheme. The infusion apparatus can effectively inhibit the adsorption of butylphthalide, greatly improve the adsorption phenomenon of the SEBS infusion apparatus to the butylphthalide, improve the utilization rate of medicines and reduce the economic burden of patients. The manner of the extrusion blow molding is not particularly limited in the present invention, and may be performed in an extrusion blow molding manner well known to those skilled in the art. Such as by means of conventional extrusion equipment, in particular a single-screw extruder. In some embodiments of the present invention, the extrusion blow molding is performed by using a single screw extruder, wherein the head temperature is 160-200 ℃, the barrel temperature is 180-190 ℃, and the residence time is 10 minutes.
For a further understanding of the invention, reference will now be made to the preferred embodiments of the invention by way of example, and it is to be understood that the description is intended to further illustrate features and advantages of the invention, and not to limit the scope of the claims.
Example 1
1.1 preparation of the Material
Weighing 70g of SEBS (with the trade name of YH506), 20g of dopamine and 10g of vitamin E, drying in an oven at 80 ℃ for 24h, and mixing uniformly; and then putting the mixture into an internal mixer for melt blending at the temperature of 180 ℃ for 10min at the rotating speed of 100rpm/min to obtain a blend. And putting the obtained blend into a granulator to extrude and granulate to obtain SEBS-based granules.
And drying the obtained SEBS-based granules in an oven at 80 ℃ for 24 hours, adding the SEBS-based granules into a single-screw extruder, extruding and drawing a tube to obtain an infusion catheter (marked as sample S1) with the diameter of 4mm, wherein the head temperature is 160-200 ℃, the barrel temperature is 180-190 ℃, the residence time is 10 minutes. The preparation process of example 1 is shown in fig. 1, and fig. 1 is a preparation process of example 1.
Preparation of the control:
an infusion catheter (designated as sample D1) of the same diameter was prepared by weighing only 70g of SEBS following the procedure described above.
1.2 Material adsorption test
The upper end of the obtained infusion catheter is connected with a needle and inserted into an infusion bottle (the liquid in the infusion bottle is butylphthalide sodium chloride injection with the specification of 100mL, 25mg of butylphthalide and 0.9g of sodium chloride), the lower part of the infusion catheter directly flows into a beaker, the flow rate is controlled to be 1mL/min, the liquid flowing out is respectively collected at 0min, 10min, 20min, 30min, 40min, 50min and 60min, a certain volume of initial liquid and the liquid flowing out at each time point are measured, the adsorption rate of the sample on butylphthalide is tested by using a high performance liquid chromatography, and the test results are shown in Table 1.
Wherein, the testing conditions of the high performance liquid chromatography are as follows: chromatographic conditions chromatographic column:
ODS-SP,5 μm,4.6 mm. times.150 mm, mobile phase: acetonitrile-water (volume ratio 30:70), detection wavelength: 228nm, volume flow: 1m L min-1Column temperature: 30 ℃, sample introduction: preparation of 20. mu.L, control solution 20.0mg of butylphthalide was weighed, dissolved in methanol and diluted into a 10mL volumetric flask as a stock solution for a standard curve.
Table 1 results of adsorptivity test of sample and control of example 1
| Adsorption time (min) | Sample D1 adsorption Rate% | Sample S1 adsorption Rate% |
| 0 | 0 | 0 |
| 10 | 7.23 | 5.32 |
| 20 | 9.92 | 5.53 |
| 30 | 9.73 | 6.21 |
| 40 | 10.15 | 6.24 |
| 50 | 10.84 | 6.32 |
| 60 | 10.87 | 7.12 |
From the above test results, it can be seen that the adsorption rate of the SEBS material (i.e., the control sample D1) to butylphthalide reaches more than 10% within 60min, while the adsorption rate of the modified material (i.e., the sample S1) to butylphthalide in example 1 is 7.12%, and thus, the SEBS-based pellet provided by the present invention can inhibit the adsorption of the material to butylphthalide.
Example 2
1.1 preparation of the Material
Weighing SEBS (the brand number is
G1652) Drying 60g, 25g of dopamine and 15g of vitamin E in an oven at 80 ℃ for 24h, and mixing uniformly; and then putting the mixture into an internal mixer for melt blending at the temperature of 180 ℃ for 10min at the rotating speed of 100rpm/min to obtain a blend. And putting the obtained blend into a granulator to extrude and granulate to obtain SEBS-based granules.
And drying the obtained SEBS-based granules in an oven at 80 ℃ for 24 hours, adding the SEBS-based granules into a single-screw extruder, extruding and drawing a tube to obtain an infusion catheter (marked as sample S2) with the diameter of 4mm, wherein the head temperature is 160-200 ℃, the barrel temperature is 180-190 ℃, the residence time is 10 minutes.
1.2 Material adsorption test
The adsorption test was performed on the obtained sample S2 according to the test procedure of example 1, and the result showed that the adsorption rate of the sample S2 to butylphthalide was 6.08% within 60 min.
Example 3
1.1 preparation of the Material
Weighing SEBS (the brand number is
7311F) Drying 90g, 5g of dopamine and 5g of vitamin E in an oven at 80 ℃ for 24h, and mixing uniformly; and then putting the mixture into an internal mixer for melt blending at the temperature of 180 ℃ for 10min at the rotating speed of 100rpm/min to obtain a blend. And putting the obtained blend into a granulator to extrude and granulate to obtain SEBS-based granules.
And drying the obtained SEBS-based granules in an oven at 80 ℃ for 24 hours, adding the SEBS-based granules into a single-screw extruder, extruding and drawing a tube to obtain an infusion catheter (marked as sample S3) with the diameter of 4mm, wherein the head temperature is 160-200 ℃, the barrel temperature is 180-190 ℃, the residence time is 10 minutes.
1.2 Material adsorption test
The adsorption test was performed on the obtained sample S3 according to the test procedure of example 1, and the result showed that the adsorption rate of the sample S3 to butylphthalide was 4.68% within 60 min.
The test results of the embodiments 1 to 3 show that the SEBS-based aggregate provided by the invention can inhibit the adsorption of the material to butylphthalide; among them, example 3, in which the raw material component ratio is in the preferable range, has the best adsorption suppressing effect.
Example 4
1.1 preparation of the Material
Weighing 60g of SEBS (trade name is YH506), 5g of dopamine and 10g of vitamin E derivative (vitamin E polyethylene glycol succinate with the number average molecular weight of 5000g/mol), drying in an oven at 80 ℃ for 24h, and mixing uniformly; and then putting the mixture into a double-screw extruder for melt blending at the temperature of 180 ℃ for 10min to obtain a blend. And putting the obtained blend into a granulator to extrude and granulate to obtain SEBS-based granules.
And drying the obtained SEBS-based granules in an oven at 80 ℃ for 24 hours, adding the SEBS-based granules into a single-screw extruder, extruding and drawing a tube to obtain an infusion catheter (marked as sample S4) with the diameter of 4mm, wherein the head temperature is 160-200 ℃, the barrel temperature is 180-190 ℃, the residence time is 10 minutes.
1.2 Material adsorption test
The resulting sample S4 was subjected to the adsorption test according to the test procedure of example 1, and the results are shown in table 2.
From the test results, the adsorption rate of the SEBS material (i.e., the control sample D1) to butylphthalide reaches more than 10% within 60min, while the adsorption rate of the modified material (i.e., the sample S4) to butylphthalide in example 4 is less than 2%, which shows that the SEBS-based pellet provided by the present invention can significantly inhibit the adsorption of the material to butylphthalide. Compared with the materials in the embodiments 1 to 3, the inhibitory effect of the vitamin E derivative on butylphthalide in the embodiment 4 is further obviously improved, and the fact that the vitamin E derivative can further obviously improve the inhibitory adsorption effect of the material on butylphthalide in the system of the invention compared with the vitamin E is proved.
Example 5
1.1 preparation of the Material
Weighing 70g of SEBS (trade name is YH506), 10g of SEBS-g-Ma (trade name is Keteng FG1901) and 10g of vitamin E derivative (vitamin E polyethylene glycol succinate with the number average molecular weight of 5000g/mol), drying in an oven at 80 ℃ for 24h, and mixing uniformly; and then putting the mixture into an internal mixer for melt blending at the temperature of 180 ℃ for 10min at the rotating speed of 100rpm/min to obtain a blend. And putting the obtained blend into a granulator to extrude and granulate to obtain SEBS-based granules.
The resulting SEBS-based pellets were oven dried at 80 ℃ for 24h and then fed into a single screw extruder and pressed into a film having a thickness of 2mm (noted as sample S5).
Preparation of the control:
a film of the same thickness (designated as sample D2) was prepared according to the above procedure except that 70g of SEBS was weighed.
1.2 Material adsorption test
After a 4cm × 4cm film is cleaned, a standard curve of butylphthalide is obtained by using an ultraviolet-visible spectrophotometer (see fig. 2), and an adsorption test of butylphthalide is performed, so that the result is shown in fig. 3, fig. 3 is an adsorption comparison graph of example 5, and the adsorption amount of SEBS material (i.e., sample D2) and the adsorption amount of butylphthalide of the material obtained in example 5 (i.e., sample S5) are shown.
The procedure of the above test method is as follows: obtaining an ultraviolet-visible spectrum curve of butylphthalide by using an ultraviolet spectrophotometer within a spectrum range of 220-700 nm at room temperature, and finding that the characteristic peak position is 276.00 nm; measuring the absorbance of the butylphthalide solution with different concentrations at the characteristic peak position of the butylphthalide, and obtaining a standard curve and a regression equation (namely, figure 2) by taking the absorbance as an abscissa and the concentration as an ordinate. And (3) at room temperature, placing the prepared blended infusion film into sealed bottles, and adding 5mL of butylphthalide solution to be detected into each bottle. According to the linear regression equation obtained by the experiment, calculating C in the weighing bottleS(concentration of unadsorbed butylphthalide solution) according to C0(initial concentration of butylphthalide solution) to calculate Cr(concentration of butylphthalide solution adsorbed by the blending infusion membrane), and then calculating M (unit adsorption mass of the blending infusion membrane). Finally, the adsorption time is taken as an abscissa and the unit adsorption mass is taken as an ordinate, and a histogram of the adsorption amount (namely, fig. 3) is prepared.
As can be seen from FIG. 3, after 72 hours, the adsorption amount of sample D2 to butylphthalide was 0.11mg/cm3As above, the modified material of the present invention (i.e., sample S5) had an adsorption amount of butylphthalide less than 0.07mg/cm3. Therefore, the material provided by the invention has a remarkable adsorption inhibition effect on butylphthalide.
Example 6
1.1 preparation of the Material
Weighing 90g of SEBS (trade name is YH506), 25g of SEBS-g-Ma (trade name is Keteng FG1901) and 15g of vitamin E derivative (polyethoxy vitamin E, the number average molecular weight is 2000g/mol), drying in an oven at 80 ℃ for 24h, and mixing uniformly; and then putting the mixture into an internal mixer for melt blending at the temperature of 180 ℃ for 10min at the rotating speed of 1000rpm/min to obtain the blend. And putting the obtained blend into a granulator to extrude and granulate to obtain SEBS-based granules.
And drying the obtained SEBS-based granules in an oven at 80 ℃ for 24 hours, adding the SEBS-based granules into a single-screw extruder, extruding and drawing a tube to obtain an infusion catheter (marked as sample S6) with the diameter of 4mm, wherein the head temperature is 160-200 ℃, the barrel temperature is 180-190 ℃, the residence time is 10 minutes.
1.2 Material adsorption test
The adsorption test was performed on the obtained sample S6 according to the test procedure of example 1, and the result showed that the adsorption rate of the sample S6 to butylphthalide was 3.62% within 60 min.
The test results of the embodiments 4 to 6 show that the material provided by the invention has an excellent adsorption inhibition effect on butylphthalide. In addition, compared with examples 1-3, the adoption of the vitamin E derivative can further obviously improve the adsorption inhibition effect on butylphthalide compared with vitamin E.
Example 7
An infusion catheter was prepared according to the procedure of example 4, except that polypropylene PP was also added to the starting material, wherein the mass ratio of SEBS to PP was 70: 30, and the sample was designated S7.
The adsorption test of sample S7 was carried out according to the test procedure of example 1, and the result showed that the adsorption rate of sample S7 to butylphthalide was 1.03% in 60 min.
Example 8
An infusion catheter was prepared according to the procedure of example 6, except that polypropylene PP was also added to the starting material, wherein the mass ratio of SEBS to PP was 70: 30, and the sample was designated S8.
The adsorption test of sample S8 was carried out according to the test procedure of example 1, and the result showed that the adsorption rate of sample S8 to butylphthalide was 2.06% within 60 min.
The above description of the embodiments is only intended to facilitate the understanding of the method of the invention and its core idea. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims (10)
1. The SEBS-based granules for the extrusion film for the infusion apparatus or the infusion apparatus are characterized by being prepared by blending and granulating the following raw materials in parts by weight:
the vitamin E-based compound is selected from one or more of vitamin E and vitamin E derivatives;
the content of the dopamine and the SEBS-g-Ma is not 0 at the same time.
2. The pellet as claimed in claim 1, wherein the number average molecular weight Mn of the SEBS is 70000 to 120000;
the grafting rate of Ma in the SEBS-g-Ma is 0.2-4%.
3. The pellet of claim 1 or 2, wherein said SEBS brand comprises YH506, vi,
G1652 and
7311FSeveral kinds of the raw materials;
the designation of SEBS-g-Ma includes FG 1901.
4. Granulate according to claim 1, characterized in that the vitamin E derivative is vitamin E polyethylene glycol succinate and/or polyethoxylated vitamin E.
5. The pellet of claim 1, wherein the feedstock further comprises polypropylene; the mass ratio of the SEBS to the polypropylene is 70: 10-50.
6. A preparation method of the SEBS-based granules for the extrusion film for the infusion set or the infusion set, which are described in any one of claims 1 to 5, is characterized by comprising the following steps:
a) melting and blending the raw materials to obtain a blend;
b) and extruding and granulating the blend to obtain SEBS-based granules.
7. The preparation method according to claim 6, wherein the melt blending temperature is 160-180 ℃ and the time is 5-10 min.
8. The method of claim 6, further comprising drying the raw materials prior to said melt blending;
the drying temperature of the raw materials is 40-120 ℃, and the drying time is 2-12 hours;
after the melt blending, further comprising drying the blend; the drying temperature of the blend is 40-80 ℃, and the drying time is 2-12 h.
9. An extruded film for infusion sets, which is characterized in that the extruded film is prepared from the SEBS-based granules disclosed in any one of claims 1-5 or the SEBS-based granules prepared by the preparation method disclosed in any one of claims 6-8 through extrusion blow molding.
10. An infusion apparatus comprises a dropping funnel and an infusion tube, and is characterized in that the dropping funnel and/or the infusion tube are/is made of SEBS-based granules through extrusion and blow molding;
the SEBS-based granular material is the SEBS-based granular material as defined in any one of claims 1 to 5 or the SEBS-based granular material prepared by the preparation method as defined in any one of claims 6 to 8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811488901.4A CN109504024B (en) | 2018-12-06 | 2018-12-06 | SEBS (styrene-ethylene-butylene-styrene) based granules, preparation method thereof, extrusion film for infusion apparatus and infusion apparatus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811488901.4A CN109504024B (en) | 2018-12-06 | 2018-12-06 | SEBS (styrene-ethylene-butylene-styrene) based granules, preparation method thereof, extrusion film for infusion apparatus and infusion apparatus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109504024A CN109504024A (en) | 2019-03-22 |
| CN109504024B true CN109504024B (en) | 2020-04-07 |
Family
ID=65753006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811488901.4A Active CN109504024B (en) | 2018-12-06 | 2018-12-06 | SEBS (styrene-ethylene-butylene-styrene) based granules, preparation method thereof, extrusion film for infusion apparatus and infusion apparatus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109504024B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111849112B (en) * | 2020-08-07 | 2021-08-17 | 中国科学院长春应用化学研究所 | Super-hydrophobic styrene thermoplastic elastomer material, preparation method thereof, infusion medical device and application |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0325129D0 (en) * | 2003-10-28 | 2003-12-03 | Smith & Nephew | Apparatus in situ |
| CN101525464B (en) * | 2009-03-12 | 2011-04-20 | 浙江三博聚合物有限公司 | Novel material for totally nontoxic non-polyvinyl chloride medical perfusion tube and method for manufacturing same |
| JP6017881B2 (en) * | 2012-08-02 | 2016-11-02 | 住友ゴム工業株式会社 | Surface modification method and surface modified elastic body |
-
2018
- 2018-12-06 CN CN201811488901.4A patent/CN109504024B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN109504024A (en) | 2019-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102388143B1 (en) | Formulation of sparingly soluble compounds by hot-melt extrusion | |
| CN103205049B (en) | Antibacterial PE film of a kind of high-barrier and preparation method thereof | |
| CN109504024B (en) | SEBS (styrene-ethylene-butylene-styrene) based granules, preparation method thereof, extrusion film for infusion apparatus and infusion apparatus | |
| CN112606360A (en) | Preparation method of melt-blown polypropylene composite material with ultrahigh melt index | |
| CN102528965A (en) | Method for producing granulates containing at least one water-soluble component | |
| CN111643456A (en) | Preparation method and application of florfenicol solid dispersion with high dissolution rate | |
| DE4127522A1 (en) | NEW MEASURES WITH A HYDROPHILE POLYMER AND DIFFERENT HYDROPHILE MATERIAL | |
| CN103202811B (en) | Diflunisal solid dispersion and preparation method thereof | |
| CN104387678A (en) | Medical thermoplastic elastomer composition and preparation method of medical tube thereof | |
| CN108727660A (en) | A kind of preparation method of low smell polyethylene composition | |
| CN102352078A (en) | Medical polyvinyl chloride (PVC) shading color paste | |
| US20050238721A1 (en) | One step compounding extrusion of drug filled polymers | |
| CN113150427A (en) | Preparation system of degradable bio-based polyethylene | |
| CN101451011A (en) | Polyolefin thermoplastic elastomer blending resin and preparation method thereof | |
| CN111688058A (en) | Plastic raw material preparation processing technology based on medical plastic product | |
| CN102336956B (en) | Special modified polypropylene resin used for cigarette filters | |
| CN103772787A (en) | Method for preparing high-concentration antistatic master batch | |
| RU2020130411A (en) | GRANULAR COMPOSITION, METHOD FOR PRODUCING GRANULAR COMPOSITION AND METHOD FOR IMPROVING DISSOLUTION PROPERTIES FOR GRANULAR COMPOSITION | |
| DE102010001425A1 (en) | Extrusion of extracts, flavors and/or vitamins to produce storage-stable granules, which are useful as food ingredients for tea and tea-like products, where long-chain inulin is used as formulation component | |
| CN107051403A (en) | The preparation method of XDI molecularly imprinted solid phase extraction column packing materials | |
| CN106620928B (en) | Composite safety transfusion device | |
| CN108102406A (en) | It is a kind of can the absorption of anti-bubble TPE infusion tube materials and preparation method thereof | |
| CN111388428B (en) | Topiramate sustained-release preparation, preparation method and application thereof | |
| CN103006568A (en) | Felodipine solid dispersion (SD) and preparation method thereof | |
| CN115895107B (en) | Polypropylene composite material and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |